Search results for "Factor V"

showing 10 items of 146 documents

[Inferior vena cava malformations and deep venous thrombosis].

2006

We carried out a prospective study of 116 patients under 50 years of age who had deep venous thrombosis of the lower extremities to determine whether the presence of congenital anomaly of the inferior vena cava (IVC) was a risk factor for the disease. All patients were investigated by Doppler echography. Some 37 patients who had iliac vein occlusion also underwent phlebography. In 10 patients in whom the IVC was difficult to image, magnetic resonance angiography or computerized axial tomography was carried out. In all patients, studies of antithrombin, protein C and protein S deficiency, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, and acquired risk factors were also p…

AdultMalemedicine.medical_specialtyTime FactorsPopliteal VeinFemoral veinVena Cava InferiorIliac VeinInferior vena cavaRecurrenceRisk FactorsmedicineFactor V LeidenConfidence IntervalsHumansProtein S deficiencyProspective StudiesVenous ThrombosisLegbusiness.industryAnticoagulantsUltrasonography DopplerGeneral MedicinePhlebographyFemoral VeinMiddle Agedmedicine.diseaseThrombosisVein occlusionSurgeryVenous thrombosisTreatment Outcomemedicine.veincardiovascular systemProthrombin G20210AFemaleRadiologybusinessTomography X-Ray ComputedMagnetic Resonance AngiographyFollow-Up StudiesRevista espanola de cardiologia
researchProduct

Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis.

2019

Multiple studies have shown that in approximately half of individuals with pulmonary embolism (PE), the deep venous thrombosis (DVT) is not evident at the moment of PE diagnosis. The underlying factors and the origin of PE in these patients are not completely understood: missed DVT, embolization of DVT in its entirety, or de-novo PE being possible explanations. The aim of this study was to evaluate the differences in PE patient with or without co-existing DVT. Sixty-three consecutive PE patients were included. Whole leg bilateral Doppler compression ultrasound was performed to all patients. The PE location and extension, C-reactive protein, platelet count, hemostatic markers FV, FVIII, FXII…

AdultMalemedicine.medical_specialtyVEIN THROMBOSISmedicine.medical_treatment030204 cardiovascular system & hematologyFibrinogenPulmonary function testing03 medical and health sciencesTHROMBOEMBOLISM0302 clinical medicineInternal medicineSCOREmedicineFactor V LeidenFACTOR-V-LEIDENHumanscardiovascular diseasesEmbolizationProspective Studiescoagulationhemostatic markersProspective cohort studydeep venous thrombosisAgedRISKVenous ThrombosisHemostasisLegbusiness.industryUltrasonography DopplerHematologyGeneral MedicineNITRIC-OXIDE MEASUREMENTSMiddle Agedmedicine.disease3. Good healthPulmonary embolismVenous thrombosis3121 General medicine internal medicine and other clinical medicineHemostasisisolated pulmonary embolismCardiologyFemalebusinessPulmonary Embolism030215 immunologymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.

2007

The role of thrombophilia and thyroid autoimmunity in unexplained infertility (UI), implantation failure (IF) and recurrent spontaneous abortion (RSA) is controversial and poorly understood.From March, 2004 to January, 2007, 119 women were prospectively included: 32 oocyte donors, 31 patients with UI, 26 with IF and 30 with RSA. The IF and RSA groups presented normal preimplantation genetic screening. Protein C, protein S, antithrombin III, lupus anticoagulant, activated protein C resistance (APCR), immunoglobulin M and G anticardiolipin antibodies, homocystine, Factor V Leiden, prothrombin G20210A mutation, methylentetrahydrofolate reductase C677T mutation, thyroid-stimulating hormone (TSH…

Adultendocrine systemmedicine.medical_specialtyAbortion Habitualmedicine.medical_treatmentThyroid GlandAutoimmunityThrombophiliaGastroenterologyIodide PeroxidaseThyroglobulinAntiphospholipid syndromeInternal medicinemedicineFactor V LeidenPrevalenceHumansThrombophiliaEmbryo ImplantationProspective StudiesUnexplained infertilityActivated Protein C ResistanceAutoantibodiesLupus anticoagulantbusiness.industryRehabilitationThyroidObstetrics and Gynecologymedicine.diseaseEndocrinologymedicine.anatomical_structureReproductive MedicineLupus Coagulation InhibitorThyroglobulinFemaleActivated protein C resistancebusinessInfertility FemaleHuman reproduction (Oxford, England)
researchProduct

“Preemptive” Live Donor Liver Transplantation for Fibrolamellar Hepatocellular Carcinoma: A Case Report

2008

Fibrolamellar (FL) hepatocellular carcinoma (HCC) is a distinctive form of primary HCC that occurs principally in children and young adults. Although liver transplantation is not contraindicated for FL-HCC, noncirrhotic patients with large HCC tumors (including FL-HCCs) are not prioritized. Although hepatic resection is considered to be the primary treatment for FL-HCC, living donor liver transplantation is evolving into a potentially better alternative. Herein we have reported successful "preemptive" living donor liver transplantation for presumed recurrence of FL-HCC after an extended right hepatectomy with resection and synthetic graft replacement of the inferior vena cava.

Adultmedicine.medical_specialtyCarcinoma HepatocellularLive donormedicine.medical_treatmentMedizinLiver transplantationInferior vena cavaGastroenterologyInternal medicineLiving DonorsmedicineHumansYoung adultneoplasmsTransplantationbusiness.industryLiver NeoplasmsFactor VCancermedicine.diseaseCombined Modality Therapydigestive system diseasesSurgeryRadiographyFibrolamellar hepatocellular carcinomamedicine.veinHepatocellular carcinomaMutationFemaleSurgerySafetyLiver cancerbusinessTransplantation Proceedings
researchProduct

Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII.

2006

Hemorrhagic shock developed in a 29-year-old nullipara without coagulopathy after emergency caesarean section. Treatment with uterotonic drugs, prostaglandins, and conservative procedures with transfusion of packed red cells and fresh-frozen plasma failed to control the diffuse vaginal and uterine bleeding. Finally an intravenous bolus injection of 90 μg/kg recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark), was given and showed success within 20 minutes after administration, without any side effects.

Adultmedicine.medical_specialtyPacked Red CellsCritical IllnessUterotonicFactor VIIa030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawPregnancyActivated factor VIImedicineCoagulopathyHumans030212 general & internal medicinepostpartum bleedingbusiness.industryCesarean SectionPostpartum HemorrhageUterine bleedingHematologyGeneral MedicineFactor VIImedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomeAnesthesiaHemorrhagic shockRecombinant DNAFemalebusinessClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemo…

2021

Abstract Introduction Individual pharmacokinetic (PK) profiling in hemophilia A (HA) helps to individualize prophylaxis using population PK models (popPK). A specific popPK model for plasma-derived factor VIII containing von-Willebrand Factor (pdFVIII/VWF) was developed. Aim To compare standard versus PK-driven prophylaxis, using a generic or a specific popPK model for pdFVIII/VWF. Materials and methods A prospective study conducted in HA patients in prophylaxis with pdFVIII/VWF (Fanhdi®) comparing three one-year study periods: (1) standard prophylaxis, (2) PK-guided prophylaxis using a generic pdFVIII popPK model which described FVIII activity irrespective of FVIII concentrate, and (3) PK-…

Adultmedicine.medical_specialtyPopulationHemophilia ABayesian methodPharmacokineticsInternal medicinehemic and lymphatic diseasesvon Willebrand FactorHemarthrosisMedicineHumansPharmacokineticsProspective StudieseducationProspective cohort studyeducation.field_of_studyFactor VIIIbusiness.industryPlasma derivedProphylaxisBayes TheoremHematologyHemarthrosismedicine.diseaseSevere moderateCohortbusinessFactor VIII vWF
researchProduct

Immune Tolerance Induction in Hemophilia A: A Review

2003

In this article, a comparative analysis of the data stemming from the studies conducted in the field of immune tolerance treatment (ITT) of hemophilia A was attempted. Comparisons are difficult because previous studies differ in many respects, including the dosage of factor (F) VIII, the number of FVIII administrations per day, the association with immunosuppressive drugs (prednisone, cyclophosphamide), and, most importantly, the definition of success in terms of the reacquisition of tolerance. However, a number of variables consistently influenced outcome: the inhibitor titer, either the maximum one or the one assayed before immune tolerance (IT) start and age. As to the FVIII dose, result…

Adultmedicine.medical_specialtyTime FactorsAdolescentDoseCyclophosphamideHemophilia AImmune toleranceVon Willebrand factorPrednisoneInternal medicineImmune ToleranceCoagulopathyHumansMedicineChildFactor VIIIbiologybusiness.industryInfantHematologymedicine.diseaseRecombinant ProteinsKineticsTreatment OutcomeChild PreschoolImmunologyChemoprophylaxisbiology.proteinCardiology and Cardiovascular MedicinebusinessBypassing agentmedicine.drugSeminars in Thrombosis and Hemostasis
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY

2008

Summary.  Background: Combined vitamin K-dependent clotting factor (VKCF) deficiency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene. Methods and results: An Italian patient with moderate to severe bleeding tendency was genotyped, and found to be homozygous for the unique VKORC1 mutation (Arg98Trp) so far detected in VKCFD2. The activity levels of VKCFs were differentially reduced, and inversely related to the previously estimated affinity of procoagulant factor propeptides for the γ-carboxylase. The normal (factor IX) or reduced antigen levels (other VKCFs) produced a gradient in specific activities. Vitamin K su…

Adultmedicine.medical_specialtycoagulation factor levelsVitamin KProtein SMixed Function OxygenasesTissue factorchemistry.chemical_compoundInternal medicineVitamin K Epoxide ReductasesmedicineVKCFD2HumansFactor IXClotting factorCoagulation factor levels; Thrombin generation; Vitamin K supplementation; VKCFD2; VKORC1 mutation;biologyFactor VIIChemistryFactor XHomozygotevitamin K supplementationHematologyBlood Coagulation DisordersEndocrinologyTreatment OutcomeCoagulationthrombin generationImmunologyMutationbiology.proteinFemaleBlood Coagulation TestsVKCFD2 VKORC1 mutation coagulation factor levels thrombin generation vitamin K supplementationProtein Cmedicine.drugHalf-LifeVKORC1 mutation
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct